[go: up one dir, main page]

MXPA02011319A - Analogos antitumorales de ecteinascidina 743. - Google Patents

Analogos antitumorales de ecteinascidina 743.

Info

Publication number
MXPA02011319A
MXPA02011319A MXPA02011319A MXPA02011319A MXPA02011319A MX PA02011319 A MXPA02011319 A MX PA02011319A MX PA02011319 A MXPA02011319 A MX PA02011319A MX PA02011319 A MXPA02011319 A MX PA02011319A MX PA02011319 A MXPA02011319 A MX PA02011319A
Authority
MX
Mexico
Prior art keywords
group
optionally protected
derivatised
antitumoral
analogs
Prior art date
Application number
MXPA02011319A
Other languages
English (en)
Inventor
Carmen Cuevas
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Priority claimed from PCT/GB2000/001852 external-priority patent/WO2000069862A2/en
Publication of MXPA02011319A publication Critical patent/MXPA02011319A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen compuestos antitumorales que tienen la estructura de ecteinascidina- de anillo fusionado de 5 miembros de la formula (XIV). Los compuestos de la presente carecen de un grupo de puente 1,4 como se encuentra en las ecteinascidinas. Tienen en la posicion C-1 un substituyente seleccionado de un grupo aminometileno opcionalmente protegido o derivatizado o un grupo hidroximetileno opcionalmente protegido o derivatizado.(ver formula).
MXPA02011319A 2000-05-15 2000-05-15 Analogos antitumorales de ecteinascidina 743. MXPA02011319A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/GB2000/001852 WO2000069862A2 (en) 1999-05-14 2000-05-15 Hemisynthetic method and intermediates thereof
PCT/GB2001/002110 WO2001087894A1 (en) 1999-05-14 2001-05-15 Antitumoral analogs of et-743

Publications (1)

Publication Number Publication Date
MXPA02011319A true MXPA02011319A (es) 2003-06-06

Family

ID=29415238

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02011319A MXPA02011319A (es) 2000-05-15 2000-05-15 Analogos antitumorales de ecteinascidina 743.

Country Status (9)

Country Link
US (3) US7247629B2 (es)
JP (1) JP5008812B2 (es)
AT (1) ATE282624T1 (es)
BG (1) BG65897B1 (es)
CA (1) CA2405002C (es)
HU (1) HU230699B1 (es)
IL (1) IL152126A (es)
MX (1) MXPA02011319A (es)
SK (1) SK287833B6 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE289810T1 (de) * 1998-05-11 2005-03-15 Pharma Mar Sa Ecteinascidinderivate
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
US7919493B2 (en) * 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
BRPI0110024B8 (pt) * 2000-04-12 2021-05-25 Pharma Mar Sa derivados de ecteinascidina antitumorais, composição farmacêutica que os compreende e uso dos mesmos
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
AU2002212499B2 (en) * 2000-11-06 2006-11-02 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
RU2359700C2 (ru) * 2004-10-26 2009-06-27 Фарма Мар С.А., Сосьедад Униперсональ Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
WO2006046079A1 (en) * 2004-10-29 2006-05-04 Pharma Mar S.A., Sociedad Unipersonal Formulations comprising ecteinascidin and a disaccharide
WO2006094012A2 (en) * 2005-03-02 2006-09-08 The Trustees Of Columbia University In The City Of New York Pentacyclic alkaloid compounds and methods of use thereof
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
RU2519750C2 (ru) * 2008-05-16 2014-06-20 Фарма Мар, С.А. Способы лечения множественной миеломы
MX2010012501A (es) * 2008-05-16 2010-12-20 Pharma Mar Sa Terapia de combinacion con un alcaloide antitumoral.
CN103038240A (zh) 2010-05-25 2013-04-10 法马马有限公司 制备海鞘素化合物的合成方法
PL2786754T3 (pl) 2010-11-12 2019-07-31 Pharma Mar S.A. Leczenie skojarzone inhibitorem mitozy
GB2519773C (en) * 2013-10-29 2018-01-03 Solus Tech Limited Mode-locking semiconductor disk laser (SDL)
CN107522698B (zh) * 2016-06-20 2021-12-28 浙江海正药业股份有限公司 一种曲贝替定的制备方法及其中间体
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
JOP20220118A1 (ar) 2019-11-21 2023-01-30 Pharma Mar Sa طرق لعلاج سرطان الرئة للخلايا الصغيرة بصيغ من لوربينيكتيدين
WO2022186221A1 (ja) * 2021-03-03 2022-09-09 国立大学法人東京大学 マクロ環含有新規テトラヒドロイソキノリンアルカロイド化合物

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
EP0309477B1 (en) 1986-06-09 1991-11-06 The Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
EP0309744A3 (de) * 1987-09-29 1989-06-28 Siemens Aktiengesellschaft Anordnung mit einem flächig sich erstreckenden Dünnfilmwellenleiter
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
ATE203534T1 (de) * 1996-01-15 2001-08-15 Janssen Pharmaceutica Nv Angiogenesis hemmende pyridazinamine
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
WO1999051238A1 (en) 1998-04-06 1999-10-14 The Board Of Trustees Of The University Of Illinois Semi-synthetic ecteinascidins
KR100603220B1 (ko) * 1998-05-05 2006-07-20 파르마 마르, 에스.에이. 고착성 해양동물의 배양방법
ATE289810T1 (de) 1998-05-11 2005-03-15 Pharma Mar Sa Ecteinascidinderivate
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
AU1325101A (en) * 1999-07-23 2001-02-13 American Superconductor Corporation Multi-layer articles and methods of making same
CA2397597A1 (en) 2000-01-19 2001-07-26 The Trustees Of Columbia University In The City Of New York Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
US6815544B2 (en) * 2000-02-11 2004-11-09 President And Fellows Of Harvard College Synthetic process for an intermediate for ecteinascidin and phthalascidin compounds
US6569859B1 (en) * 2000-02-22 2003-05-27 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
BRPI0110024B8 (pt) 2000-04-12 2021-05-25 Pharma Mar Sa derivados de ecteinascidina antitumorais, composição farmacêutica que os compreende e uso dos mesmos
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
US20020137663A1 (en) * 2000-08-11 2002-09-26 Forman Barry M. The anti-neoplastic agent ET-743 inhibits trans activation by SXR
AU2002212499B2 (en) * 2000-11-06 2006-11-02 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
EP1360337A1 (en) 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
US20050004018A1 (en) 2001-10-19 2005-01-06 Jose Jimeno Use of antitumoral compound in cancer therapy
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0218813D0 (en) * 2002-08-13 2002-09-18 Pharma Mar Sa DNA sequences from an endosymbiont and their uses
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
CA2544320A1 (en) 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Method of treating cancer using a combination comprising et-743 and 5-fluorouracil
CN1897949A (zh) 2003-11-14 2007-01-17 马尔药品公司 包含使用et－743和紫杉醇来治疗癌症的联合疗法
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080242670A2 (en) 2004-09-29 2008-10-02 Pharma Mar S.A., Sociedad Unipersonal Anti-Inflammatory Agents
RU2359700C2 (ru) 2004-10-26 2009-06-27 Фарма Мар С.А., Сосьедад Униперсональ Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
WO2006046079A1 (en) * 2004-10-29 2006-05-04 Pharma Mar S.A., Sociedad Unipersonal Formulations comprising ecteinascidin and a disaccharide
EP2201141A1 (en) 2007-10-19 2010-06-30 Pharma Mar S.A. Prognostic molecular markers for et-743 treatment
RU2519750C2 (ru) 2008-05-16 2014-06-20 Фарма Мар, С.А. Способы лечения множественной миеломы
MX2010012501A (es) 2008-05-16 2010-12-20 Pharma Mar Sa Terapia de combinacion con un alcaloide antitumoral.

Also Published As

Publication number Publication date
CA2405002C (en) 2010-09-21
SK287833B6 (sk) 2011-11-04
ATE282624T1 (de) 2004-12-15
IL152126A (en) 2013-04-30
IL152126A0 (en) 2003-05-29
US8012975B2 (en) 2011-09-06
CA2405002A1 (en) 2001-11-22
BG65897B1 (bg) 2010-04-30
US7247629B2 (en) 2007-07-24
US20040019056A1 (en) 2004-01-29
HK1053653A1 (en) 2003-10-31
HUP0302327A2 (hu) 2003-10-28
US20060019960A1 (en) 2006-01-26
HUP0302327A3 (en) 2006-05-29
JP5008812B2 (ja) 2012-08-22
HU230699B1 (hu) 2017-09-28
JP2003533532A (ja) 2003-11-11
US20080051407A1 (en) 2008-02-28
US7410969B2 (en) 2008-08-12
SK16012002A3 (sk) 2003-05-02
BG107302A (bg) 2003-07-31

Similar Documents

Publication Publication Date Title
MXPA02011319A (es) Analogos antitumorales de ecteinascidina 743.
MXPA02011977A (es) Herbicidas de piridina sustituidas.
MA26770A1 (fr) Diarylamines substituees par 1-heterocycle.
EA200300429A1 (ru) Способ получения порошковых композиций
GB0013407D0 (en) Forms of a chemical compound
CY1108095T1 (el) Αντικαρκινικα αναλογα της ετ-743
WO2002098856A3 (en) Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists
PL367940A1 (en) Antitumoral analogs
MXPA02012033A (es) Derivados de 2-aminocarbonil-9h-purina.
NZ527867A (en) Oral pharmaceutical composition of cefpodoxime proxetil
MXPA02012271A (es) Nuevos compuestos que poseen actividad antibacteriana, antifungal o antitumor.
AU2002239344A1 (en) Pyrazolopyridines
EA199900373A2 (ru) Фармацевтические композиции
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
MXPA02012752A (es) Agentes herbicidas.
MXPA02011370A (es) Iminoazinas substituidas.
YU80902A (sh) Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže
HUP0400648A3 (en) Compositions for antitumour treatment containing ecteinascidin 743
TR200002380T2 (tr) Yeni triazolo (4,5-d) pirimidin bileşikleri
WO2002000638A3 (en) Substituted phthalides as anti-convulsive drugs
AU2956302A (en) A process for the preparation of taxan derivatives
MXPA02007973A (es) Compuestos de aminoacidos y su uso como inhibidores de nep, ace y ece.
MY138865A (en) New tricyclic azepine compounds, a process for their preparation and pharmaceutical compositions containing them
WO2002030859A3 (de) Tertiäre divinylether, verfahren zu deren herstellung und deren verwendung
MY103631A (en) Certain insecticidal 6-(phenoxy-2-pyridyl)-methyl-neo-phental ethers

Legal Events

Date Code Title Description
FG Grant or registration